SBRT Clinical Trials

4 recruiting

SBRT Trials at a Glance

11 actively recruiting trials for sbrt are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Guangzhou, Zamość, and Changsha. Lead sponsors running sbrt studies include Affidea Nu-med Center of Oncological DIagnostics and Therapy, Fang Wu, and Brigham and Women's Hospital.

Browse sbrt trials by phase

Treatments under study

About SBRT Clinical Trials

Looking for clinical trials for SBRT? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new SBRT trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about SBRT clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 2Phase 3

PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer

Prostate CancerBrachytherapyStereotactic Body Radiation Therapy (SBRT)+2 more
Affidea Nu-med Center of Oncological DIagnostics and Therapy1,600 enrolled1 locationNCT07426094
Recruiting
Phase 2

The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer

NSCLCImmunotherapyStereotactic Body Radiation Therapy (SBRT)
Fudan University27 enrolled1 locationNCT06738160
Recruiting
Phase 2Phase 3

PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer

Prostate Cancer (Adenocarcinoma)Stereotactic Body Radiation Therapy (SBRT)Localized Prostate Cancer+2 more
Affidea Nu-med Center of Oncological DIagnostics and Therapy1,200 enrolled1 locationNCT07426055
Recruiting
Not Applicable

Practical Geriatric Assessment in Older Adults With Non-Small Cell Lung Cancer Undergoing Stereotactic Body Radiation Therapy

Lung Cancer (NSCLC)Geriatric AssessmentStereotactic Body Radiation Therapy (SBRT)
Brigham and Women's Hospital64 enrolled1 locationNCT06987890
Recruiting

Single-Fraction Pulmonary Ablative Radiotherapy Outcomes and Quality-of-life Workup

NSCLC (Non-small Cell Lung Cancer)Oligometastatic Lung TumorSBRT
Institut du Cancer de Montpellier - Val d'Aurelle190 enrolled2 locationsNCT07441941
Recruiting

The Effectiveness and Safety of SBRT in the Treatment of Patients With MPLC After Surgery (SMILE)

The Efficacy and Safety of SBRT in MPLC
Fang Wu40 enrolled5 locationsNCT05113017
Recruiting

SMC Radiation Oncology SABR Cohort for Oligometastasis

OligometastasisctDNAPatient-Reported Outcomes (PRO)+2 more
Samsung Medical Center60 enrolled1 locationNCT07121335
Recruiting
Phase 2

SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy

ImmunotherapySBRTNasopharyngeal Cancinoma (NPC)
The First Affiliated Hospital of Xiamen University20 enrolled2 locationsNCT06676722
Recruiting

Systemic Anti-tumor Activity and Safety of the Combination of SBRT and Concurrent PD-1 Blockade in Metastatic RCC.

Systemic Anti-tumor Activity and Safety of the Combination of SBRT and Concurrent PD-1 Blockade in Metastatic RCC
Nanfang Hospital, Southern Medical University20 enrolled1 locationNCT06327178
Recruiting

Observational Study on Extreme Hypofractionation for Localized Prostate Cancer

Prostate CancerRadiotherapySBRT
Universitaire Ziekenhuizen KU Leuven246 enrolled1 locationNCT05344235
Recruiting
Phase 2

SBRT Followed by Neoadjuvant Chemoimmunotherapy of Sindilizumab Plus Docetaxel and Cisplatin for Locoregionally Advanced Squamous Carcinoma of Oral Cavity and Oropharynx

SBRT
Sun Yat-sen University25 enrolled1 locationNCT06219980